CD274 and neoplasm: Despite the overall similar PD‐L1 results in the RTD patients, if a 50% positivity cut‐off were used to guide immunotherapy, the results of PD‐L1 testing at different tumor sites would be discordant in 60% (3 of 5) and 20% (1 of 5) of patients tested with the E1L3N and 28‐8 clones, respectively.